Bone Marrow Transplant Clinical Trials - CSL Behring CSL964_2001

Bone marrow transplant

Status:

Open (Study open and enrolling)

ClinicalTrials.gov:

CONDITION(S): Graft Versus Host Disease - TRIAL: CSL Behring CSL964_2001 - The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft‑Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant (MODULAATE).

This study is a Phase 2/3 prospective, double-blind, randomized, multi-center, placebo‑controlled study for prevention of acute GVHD (aGVHD) in subjects undergoing an allogeneic hematopoietic cell transplant (HCT).

Drug

Biological: Alpha-1 antitrypsin (AAT)Biological: Placebo

Trial Type

Interventional

Phase

Phase 2/3

Condition

Graft Versus Host Disease (GVHD)

Keywords

Graft Versus Host Disease (GVHD) | CSL Behring CSL964_2001

Bone Marrow Transplant Clinical Trials - CSL Behring CSL964_2001